[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[2] DY G W,GORE J L,FOROUZANFAR M H,et al.Global Burden of Urologic Cancers,1990-2013[J]. Eur Urol, 2017,71(3):437-446.
[3] CASEY R G, CATTO J W, CHENG L, et al.Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract:a systematic review[J].Eur Urol,2015,67(5):876-88.
[4] GOPALAKRISHNA A, FANTONY J J, LONGO T A, et al.Anticipatory positive urine tests for bladder cancer[J].Ann Surg Oncol,2017,24(6):1747-1753.
[5] DI STASI S M, DE CARLO F, PAGLIARULO V, et al. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder[J].Ther Adv Urol,2015,7(6):339-350.
[6] ROSE J B, ARMSTRONG S, HERMANN G G, et al.Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden[J]. BJU Int, 2016, 117(6B): E102-E113.
[7] Whitmore WF Jr, Bush IM, Esquivel E.Tetracycline ultraviolet fluorescence in bladder carcinoma[J]. Cancer,1964,17:1528-1532.
[8] GEAVLETE B F, BRINZEA A, CHECHERIŢĂ I A, et al.Carcinoma in situ of the urinary bladder-from pathology to narrow band imaging[J]. Rom J Morphol Embryol, 2015, 56(3): 1069-1076.
[9] XIONG Y, LI J, MA S, et al.A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer[J]. PLoS One, 2017, 12(2): e0170819.
[10] KOBATAKE K, MITA K, OHARA S, et al.Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer[J]. Oncol Lett, 2015, 10(2): 1097-1102.
[11] MIYAKE M, MORIZAWA Y, HORI S, et al.Diagnostic and prognostic role of urinary collagens in primary human bladder cancer[J]. Cancer Sci, 2017, 108(11): 2221-2228.
[12] TODENHÖFER T, HENNENLOTTER J, GUTTENBERG P, et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer[J]. BMC Cancer, 2015, 15: 155.
[13] MISCHINGER J, GUTTENBERG L P, HENNENLOTTER J, et al.Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization[J]. J Cancer Res Clin Oncol, 2017, 143(4): 677-685.
[14] ECKE T H, WEIß C, STEPHAN C, et al.UBC® Rapid Test for detection of carcinoma in situ for bladder cancer[J]. Tumour Biol, 2017, 39(5): 1010428317701624.
[15] PICHLER R, TULCHINER G, FRITZ J, et al.Urinary UBC Rapid and NMP22 Test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study[J]. Int J Med Sci, 2017, 14(9): 811-819.
[16] BIRKENKAMP-DEMTRÖDER K, NORDENTOFT I, CHRISTENSEN E, et al. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer[J]. Eur Urol, 2016, 70(1): 75-82.
[17] GAZZANIGA P, GRADILONE A, DE BERARDINIS E, et al.Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer:a CellSearch analysis[J]. Ann Oncol, 2012, 23(9): 2352-2356.
[18] HERR H W.Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy[J]. J Urol, 2005, 174(6): 2134-2137.
[19] ODDENS J, BRAUSI M, SYLVESTER R, et al.Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder:one-third dose versus full dose and 1 year versus 3 years of maintenance[J]. Eur Urol, 2013, 63(3): 462-472.
[20] MARTÍNEZ-PIÑEIRO L, PORTILLO J A, FERNÁNDEZ J M, et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma:Final Results of Randomised CUETO Study 98013[J]. Eur Urol, 2015, 68(2): 256-262.
[21] PHILIPS G K, ATKINS M.Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies[J]. Int Immunol, 2015, 27(1): 39-46.
[22] GALLAGHER K M, GRAY K, ANDERSON C H, et al.‘Real-life experience': recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study[J]. World J Urol, 2017, 35(12): 1871-1877.
[23] THOMAS F,NOON A P,RUBIN N,et al.Comparative outcomes of primary,recurrent, and progressive high-risk non-muscle-invasive bladder cancer[J]. Eur Urol,2013,63(1): 145-154.
[24] 李亚伟,黄后宝,卓栋,等.经尿道海博刀黏膜下剥离整块切除非肌层浸润性膀胱癌的初步研究[J].临床泌尿外科杂志,2018,33(11):870-873.
[25] KRAMER M W, ALTIERI V, HURLE R, et al.Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer[J]. Eur Urol Focus, 2017, 3(6): 567-576.
[26] STEINBERG R L, THOMAS L J, NEPPLE K G.Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin[J]. Urol Oncol, 2016, 34(6): 279-289.
[27] LEE J Y, DIAZ R R, CHO K S, et al.Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy[J]. J Urol,2013,190(4):1192-1199.
[28] HEDEGAARD J, LAMY P, NORDENTOFT I, et al.Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma[J]. Cancer Cell, 2016, 30(1): 27-42. |
